TrialGlobe

Clinical trial

Integrated Multi-omics Data for Personalized Treatment of Obesity-associated Fatty Liver Disease

Recruiting now · Not applicable · 1 countries · Registry ID NCT05554224

Recruiting nowNot applicableObservational

What this study is about

The investigators seek to analyze the samples provided by patients with obesity-associated fatty liver disease at the multi-omics level and to integrate the results with clinical information, genotypic variants, and factors influencing inter-organ crosstalk. The main aim is to improve the interpretation of fatty liver disease associated with obesity and diabetes by developing predictive models built with algorithms from artificial intelligence. The challenge is to decipher the flow of information by exploring contributing factors, proximate causes of regulatory defects, and maladaptive responses that may promote therapeutic approaches.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionNAFLD, Obesity, Morbid, Comorbidities and Coexisting Conditions

Full registry criteria

Inclusion Criteria: * Body mass index greater or equal to 40 kg/m\^2. * Body mass index between 35 and 40 kg/m\^2 with high-risk comorbidities (diagnosis or treatment for hypertension, dyslipidemia, or type 2 diabetes mellitus). * Positive psychiatric evaluation. * Age greater or equal to 18 years old. Exclusion Criteria: * Legal or illegal drug consumption, including alcohol. * Diagnosis of Hepatitis. * Current cancer diagnosis or treatment. * Clinical or analytical evidence of severe illness. * Clinical or analytical evidence of chronic or acute inflammation. * Clinical or analytical evidence of infectious diseases. * Clinical or analytical evidence of terminal illness.

Treatments and study arms

To propose diagnostic tests for liver diseases before surgical decisions.

Diagnostic Test

Observational although patients are candidates for metabolic surgery.

Primary outcomes

Weight change1 to 10 years

The effect of bariatric surgery on adiposity outcomes.

Type 2 diabetes mellitus incidence1 to 10 years

The effect of bariatric surgery on metabolic outcomes.

Hypertension incidence1 to 10 years

The effect of bariatric surgery on metabolic outcomes.

Chronic liver diseases incidence1 to 10 years

The usefulness of imaging techniques on metabolic outcomes.

Dyslipidemia incidence1 to 10 years

The effect of bariatric surgery on metabolic outcomes.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Hospital Universitari Sant Joan🇪🇸 Reus, Tarragona, Spain
Open map
Jorge Joven, ProfessorContact
Email · Call +34977310300
Jorge Joven, ProfessorContact
Daniel del Castillo, ProfessorContact